Giant cell arteritis

Headache

Volumn 54, Issue 8, 2014, Pages 1273-1289

  Smith, Jonathan H ^a   Swanson, Jerry W ^b  

^a UNIVERSITY OF KENTUCKY   (United States)

^b MAYO CLINIC   (United States)

Author keywords

cranial arteritis; elderly; giant cell arteritis; older adult; secondary headache; temporal arteritis

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CORTICOSTEROID; DAPSONE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR;

ABDOMINAL AORTA ANEURYSM; ANGIOGRAPHY; ANTICOAGULANT THERAPY; AORTA DISSECTION; ARTERY OCCLUSION; BIOPSY; BLINDNESS; CEREBROVASCULAR DISEASE; CERVICAL MYELOPATHY; CERVICOBRACHIAL NEURALGIA; CLINICAL FEATURE; COLOR ULTRASOUND FLOWMETRY; CORTICOSTEROID INDUCED MYOPATHY; CORTICOSTEROID THERAPY; CRANIAL NEUROPATHY; DIPLOPIA; ERYTHROCYTE SEDIMENTATION RATE; GIANT CELL ARTERITIS; HEADACHE; HUMAN; INCIDENCE; LOW DRUG DOSE; NUCLEAR MAGNETIC RESONANCE IMAGING; OPHTHALMOPLEGIA; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; REVIEW; THORACIC AORTA ANEURYSM; VISUAL IMPAIRMENT;

GIANT CELL ARTERITIS; HUMANS;

EID: 84908263445     PISSN: 00178748     EISSN: 15264610     Source Type: Journal    
DOI: 10.1111/head.12425     Document Type: Review

References (170)

1. Hunder GG, Bloch DA, Michel BA, et al. The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis. Arthritis Rheum. 1990; 33: 1122-1128.
2. Grayson PC, Maksimowicz-McKinnon K, Clark TM, et al. Distribution of arterial lesions in Takayasu's arteritis and giant cell arteritis. Ann Rheum Dis. 2012; 71: 1329-1334.
3. Appelboom T, van Eigem A,. How ancient is temporal arteritis? J Rheumatol. 1990; 17: 929-931.
4. Boes CJ,. Bayard Horton's clinicopathological description of giant cell (temporal) arteritis. Cephalalgia. 2007; 27: 68-75.
5. Schmidt M,. Intracranial aneurysms. Brain. 1930; 53: 489-540.
6. Jennings GH,. Arteritis of the temporal vessels. Lancet. 1938; 1: 424-428.
7. Gilmour JR,. Giant cell chronic arteritis. J Pathol Bacteriol. 1941; 53: 263-277.
8. Hunder GG,. The early history of giant cell arteritis and polymyalgia rheumatica: First descriptions to 1970. Mayo Clin Proc. 2006; 81: 1071-1083.
9. Huston KA, Hunder GG, Lie JT, Kennedy RH, Elveback LR,. Temporal arteritis: A 25-year epidemiologic, clinical, and pathologic study. Ann Intern Med. 1978; 88: 162-167.
10. Kleindorfer DO, Khoury J, Moomaw CJ, et al. Stroke incidence is decreasing in whites but not in blacks: A population-based estimate of temporal trends in stroke incidence from the Greater Cincinnati/Northern Kentucky Stroke Study. Stroke. 2010; 41: 1326-1331.
11. Salvarani C, Gabriel SE, O'Fallon WM, Hunder GG,. The incidence of giant cell arteritis in Olmsted County, Minnesota: Apparent fluctuations in a cyclic pattern. Ann Intern Med. 1995; 123: 192-194.
12. Salvarani C, Crowson CS, O'Fallon WM, Hunder GG, Gabriel SE,. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum. 2004; 51: 264-268.
13. Kisza K, Murchison AP, Dai Y, et al. Giant cell arteritis incidence: Analysis by season and year in mid-Atlantic United States. Clin Experiment Ophthalmol. 2013; 41: 577-581.
14. Kobayashi S, Fujimoto S,. Epidemiology of vasculitides: Differences between Japan, Europe and North America. Clin Exp Nephrol. 2013; 17: 611-614.
15. Herlyn K, Buckert F, Gross WL, Reinhold-Keller E,. Doubled prevalence rates of ANCA-associated vasculitides and giant cell arteritis between 1994 and 2006 in northern Germany. Rheumatology. 2014; 53: 882-889.
16. Machado EB, Michet CJ, Ballard DJ, et al. Trends in incidence and clinical presentation of temporal arteritis in Olmsted County, Minnesota, 1950-1985. Arthritis Rheum. 1988; 31: 745-749.
17. Kobayashi S, Yano T, Matsumoto Y, et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: The first government-supported nationwide survey. Arthritis Rheum. 2003; 49: 594-598.
18. Ostberg G,. An arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand Suppl. 1973; 237 (Suppl. 237): 231-259.
19. Wilkinson IM, Russell RW,. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol. 1972; 27: 378-391.
20. Bley TA, Weiben O, Uhl M, et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum. 2005; 52: 2470-2477.
21. Ghinoi A, Pipitone N, Nicolini A, et al. Large-vessel involvement in recent-onset giant cell arteritis: A case-control colour-Doppler sonography study. Rheumatology. 2012; 51: 730-734.
22. Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in biopsy-proven giant cell arteritis: Prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis. 2012; 71: 1170-1176.
23. Evans JM, O'Fallon WM, Hunder GG,. Increased incidence of aortic aneurysm and dissection in giant cell (temporal) arteritis. A population-based study. Ann Intern Med. 1995; 122: 502-507.
24. Evans JM, Bowles CA, Bjornsson J, Mullany CJ, Hunder GG,. Thoracic aortic aneurysm and rupture in giant cell arteritis. A descriptive study of 41 cases. Arthritis Rheum. 1994; 37: 1539-1547.
25. Caselli RJ, Hunder GG, Whisnant JP,. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology. 1988; 38: 352-359.
26. Solomon S, Cappa KG,. The headache of temporal arteritis. J Am Geriatr Soc. 1987; 35: 163-165.
27. Jimenez-Jimenez FJ, Garcia-Albea E, Zurdo M, Martinez-Onsurbe P, Ruiz de Villaespesa A,. Giant cell arteritis presenting as cluster headache. Neurology. 1998; 51: 1767-1768.
28. Rozen TD,. Brief sharp stabs of head pain and giant cell arteritis. Headache. 2010; 50: 1516-1519.
29. Smetana GW, Shmerling RH,. Does this patient have temporal arteritis? JAMA. 2002; 287: 92-101.
30. Aiello PD, Trautmann JC, McPhee TJ, Kunselman AR, Hunder GG,. Visual prognosis in giant cell arteritis. Ophthalmology. 1993; 100: 550-555.
31. Wagener HP, Hollenhorst RW,. The ocular lesions of temporal arteritis. Am J Ophthalmol. 1958; 45: 617-630.
32. Galetta SL, Balcer LJ, Liu GT,. Giant cell arteritis with unusual flow-related neuro-ophthalmologic manifestations. Neurology. 1997; 49: 1463-1465.
33. Miller NR,. Visual manifestations of temporal arteritis. Rheum Dis Clin North Am. 2001; 27: 781-797.
34. Morotti A, Liberini P, Padovani A,. Bilateral optic perineuritis as the presenting feature of giant cell arteritis. BMJ Case Reports. 2013; 2013.
35. Barricks ME, Traviesa DB, Glaser JS, Levy IS,. Ophthalmoplegia in cranial arteritis. Brain. 1977; 100: 209-221.
36. Dimant J, Grob D, Brunner NG,. Ophthalmoplegia, ptosis, and miosis in temporal arteritis. Neurology. 1980; 30: 1054-1058.
37. Garcia-Garcia J, Ayo-Martin O, Argandona-Palacios L, Segura T,. Vertebral artery halo sign in patients with stroke: A key clue for the prompt diagnosis of giant cell arteritis. Stroke. 2011; 42: 3287-3290.
38. Howard GF 3rd, Ho SU, Kim KS, Wallach J,. Bilateral carotid artery occlusion resulting from giant cell arteritis. Ann Neurol. 1984; 15: 204-207.
39. Pfefferkorn T, Schuller U, Cyran C, et al. Giant cell arteritis of the basal cerebral arteries: Correlation of MRI, DSA, and histopathology. Neurology. 2010; 74: 1651-1653.
40. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Gomez-Acebo I, et al. Strokes at time of disease diagnosis in a series of 287 patients with biopsy-proven giant cell arteritis. Medicine. 2009; 88: 227-235.
41. Zenone T, Puget M,. Characteristics of cerebrovascular accidents at time of diagnosis in a series of 98 patients with giant cell arteritis. Rheumatol Int. 2013; 33: 3017-3023.
42. Solans-Laque R, Bosch-Gil JA, Molina-Catenario CA, Ortega-Aznar A, Alvarez-Sabin J, Vilardell-Tarres M,. Stroke and multi-infarct dementia as presenting symptoms of giant cell arteritis: Report of 7 cases and review of the literature. Medicine. 2008; 87: 335-344.
43. Nesher G, Berkun Y, Mates M, Baras M, Rubinow A, Sonnenblick M,. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum. 2004; 50: 1332-1337.
44. Narvaez J, Bernad B, Gomez-Vaquero C, et al. Impact of antiplatelet therapy in the development of severe ischemic complications and in the outcome of patients with giant cell arteritis. Clin Exp Rheumatol. 2008; 26: S57-S62.
45. Lee MS, Smith SD, Galor A, Hoffman GS,. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum. 2006; 54: 3306-3309.
46. Schon F,. Involvement of smell and taste in giant cell arteritis. J Neurol Neurosurg Psychiatry. 1988; 51: 1594.
47. Jay WM, Nazarian SM,. Bilateral sixth nerve pareses with temporal arteritis and diabetes. J Clin Neuroophthalmol. 1986; 6: 91-95.
48. Tamhankar MA, Biousse V, Ying GS, et al. Isolated third, fourth, and sixth cranial nerve palsies from presumed microvascular vs other causes: A prospective study. Ophthalmology. 2013; 120: 2264-2269.
49. Roomet A, Allen JS,. Temporal arteritis heralded by facial nerve palsy. JAMA. 1974; 228: 870-871.
50. Amor-Dorado JC, Llorca J, Garcia-Porrua C, Costa C, Perez-Fernandez N, Gonzalez-Gay MA,. Audiovestibular manifestations in giant cell arteritis: A prospective study. Medicine. 2003; 82: 13-26.
51. Gout O, Viala K, Lyon-Caen O,. Giant cell arteritis and Vernet's syndrome. Neurology. 1998; 50: 1862-1864.
52. Katelaris CH, Walls RS,. Fatal neurological complications in temporal arteritis: An unusual case. Aust N Z J Med. 1982; 12: 299-302.
53. Galetta SL, Balcer LJ, Lieberman AP, Syed NA, Lee JM, Oberholtzer JC,. Refractory giant cell arteritis with spinal cord infarction. Neurology. 1997; 49: 1720-1723.
54. Gibb WR, Urry PA, Lees AJ,. Giant cell arteritis with spinal cord infarction and basilar artery thrombosis. J Neurol Neurosurg Psychiatry. 1985; 48: 945-948.
55. Brennan MJ, Sandyk R,. Reversible quadriplegia in a patient with giant-cell arteritis. S Afr Med J. 1982; 62: 81-82.
56. Rivest D, Brunet D, Desbiens R, Bouchard JP,. C-5 radiculopathy as a manifestation of giant cell arteritis. Neurology. 1995; 45: 1222-1224.
57. Shapiro L, Medsger TA Jr, Nicholas JJ,. Brachial plexitis mimicking C5 radiculopathy-A presentation of giant cell arteritis. J Rheumatol. 1983; 10: 670-671.
58. Soubrier M, Dubost JJ, Tournadre A, Deffond D, Clavelou P, Ristori JM,. Cervical radiculopathy as a manifestation of giant cell arteritis. Joint Bone Spine. 2002; 69: 316-318.
59. Massey EW, Weed T,. Sciatic neuropathy with giant-cell arteritis. N Engl J Med. 1978; 298: 917.
60. Feigal DW, Robbins DL, Leek JC,. Giant cell arteritis associated with mononeuritis multiplex and complement-activating 19S IgM rheumatoid factor. Am J Med. 1985; 79: 495-500.
61. Schwedt TJ, Hunder GG, Dodick DW,. Giant cell arteritis and polymyalgia rheumatic. In:, Silberstein SD, Lipton RB, Dodick DW, eds. Wolff's Headache and Other Head Pain, 8th edn. New York, New York: Oxford University Press; 2008: 651-662.
62. Abilleira S, Bowler JV,. The numb chin syndrome as an early manifestation of giant-cell (temporal) arteritis: A case report. Headache. 2005; 45: 1411-1413.
63. Healey LA, Wilske KR,. Presentation of occult giant cell arteritis. Arthritis Rheum. 1980; 23: 641-643.
64. Calamia KT, Hunder GG,. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum. 1981; 24: 1414-1418.
65. Zenone T, Puget M,. Dry cough is a frequent manifestation of giant cell arteritis. Rheumatol Int. 2013; 33: 2165-2168.
66. Hellmann DB,. Temporal arteritis: A cough, toothache, and tongue infarction. JAMA. 2002; 287: 2996-3000.
67. Nir-Paz R, Gross A, Chajek-Shaul T,. Reduction of jaw opening (trismus) in giant cell arteritis. Ann Rheum Dis. 2002; 61: 832-833.
68. Klein RG, Hunder GG, Stanson AW, Sheps SG,. Large artery involvement in giant cell (temporal) arteritis. Ann Intern Med. 1975; 83: 806-812.
69. Nuenninghoff DM, Hunder GG, Christianson TJ, McClelland RL, Matteson EL,. Incidence and predictors of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis: A population-based study over 50 years. Arthritis Rheum. 2003; 48: 3522-3531.
70. Scola CJ, Li C, Upchurch KS,. Mesenteric involvement in giant cell arteritis. An underrecognized complication? Analysis of a case series with clinicoanatomic correlation. Medicine. 2008; 87: 45-51.
71. Myklebust G, Gran JT,. A prospective study of 287 patients with polymyalgia rheumatica and temporal arteritis: Clinical and laboratory manifestations at onset of disease and at the time of diagnosis. Br J Rheumatol. 1996; 35: 1161-1168.
72. Grayson PC, Tomasson G, Cuthbertson D, et al. Association of vascular physical examination findings and arteriographic lesions in large vessel vasculitis. J Rheumatol. 2012; 39: 303-309.
73. Liou LM, Khor GT, Lan SH, Lai CL,. Giant cell arteritis with multiple cranial nerve palsy and reversible proptosis: A case report. Headache. 2007; 47: 1451-1453.
74. Tsianakas A, Ehrchen JM, Presser D, et al. Scalp necrosis in giant cell arteritis: Case report and review of the relevance of this cutaneous sign of large-vessel vasculitis. J Am Acad Dermatol. 2009; 61: 701-706.
75. Husein-Elahmed H, Callejas-Rubio JL, Rios-Fernandez R, Ortego-Centeno N,. Tongue infarction as first symptom of temporal arteritis. Rheumatol Int. 2012; 32: 799-800.
76. Kermani TA, Schmidt J, Crowson CS, et al. Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum. 2012; 41: 866-871.
77. Salvarani C, Hunder GG,. Giant cell arteritis with low erythrocyte sedimentation rate: Frequency of occurrence in a population-based study. Arthritis Rheum. 2001; 45: 140-145.
78. Ellis ME, Ralston S,. The ESR in the diagnosis and management of the polymyalgia rheumatica/giant cell arteritis syndrome. Ann Rheum Dis. 1983; 42: 168-170.
79. Miller A, Green M, Robinson D,. Simple rule for calculating normal erythrocyte sedimentation rate. Br Med J. 1983; 286: 266.
80. Gonzalez-Gay MA, Lopez-Diaz MJ, Barros S, et al. Giant cell arteritis: Laboratory tests at the time of diagnosis in a series of 240 patients. Medicine. 2005; 84: 277-290.
81. Rison RA,. Branch facial nerve trauma after superficial temporal artery biopsy: A case report. J Med Case Rep. 2011; 5: 34.
82. Achkar AA, Lie JT, Hunder GG, O'Fallon WM, Gabriel SE,. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis? Ann Intern Med. 1994; 120: 987-992.
83. Narvaez J, Bernad B, Roig-Vilaseca D, et al. Influence of previous corticosteroid therapy on temporal artery biopsy yield in giant cell arteritis. Semin Arthritis Rheum. 2007; 37: 13-19.
84. Gabriel SE, O'Fallon WM, Achkar AA, Lie JT, Hunder GG,. The use of clinical characteristics to predict the results of temporal artery biopsy among patients with suspected giant cell arteritis. J Rheumatol. 1995; 22: 93-96.
85. McGee S,. Simplifying likelihood ratios. J Gen Intern Med. 2002; 17: 646-649.
86. Boyev LR, Miller NR, Green WR,. Efficacy of unilateral vs bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol. 1999; 128: 211-215.
87. Klein RG, Campbell RJ, Hunder GG, Carney JA,. Skip lesions in temporal arteritis. Mayo Clin Proc. 1976; 51: 504-510.
88. Breuer GS, Nesher G, Nesher R,. Rate of discordant findings in bilateral temporal artery biopsy to diagnose giant cell arteritis. J Rheumatol. 2009; 36: 794-796.
89. Pless M, Rizzo JF 3rd, Lamkin JC, Lessell S,. Concordance of bilateral temporal artery biopsy in giant cell arteritis. J Neuro Ophthalmol. 2000; 20: 216-218.
90. Ypsilantis E, Courtney ED, Chopra N, et al. Importance of specimen length during temporal artery biopsy. Br J Surg. 2011; 98: 1556-1560.
91. Breuer GS, Nesher R, Nesher G,. Effect of biopsy length on the rate of positive temporal artery biopsies. Clin Exp Rheumatol. 2009; 27: S10-S13.
92. Su GW, Foroozan R, Yen MT,. Quantitative analysis of temporal artery contraction after biopsy for evaluation of giant cell arteritis. Canadian J Ophthalmol Journal Canadien D'Ophtalmologie. 2006; 41: 500-503.
93. Achkar AA, Lie JT, Gabriel SE, Hunder GG,. Giant cell arteritis involving the facial artery. J Rheumatol. 1995; 22: 360-362.
94. Albornoz MA, Sharit S, Myers AR,. Multi-vessel biopsy-proven giant cell arteritis involving the occipital and temporal arteries. J Clin Rheumatol. 1997; 3: 227-229.
95. Brack A, Martinez-Taboada V, Stanson A, Goronzy JJ, Weyand CM,. Disease pattern in cranial and large-vessel giant cell arteritis. Arthritis Rheum. 1999; 42: 311-317.
96. Arida A, Kyprianou M, Kanakis M, Sfikakis PP,. The diagnostic value of ultrasonography-derived edema of the temporal artery wall in giant cell arteritis: A second meta-analysis. BMC Musculoskelet Disord. 2010; 11: 44.
97. Maldini C, Depinay-Dhellemmes C, Tra TT, et al. Limited value of temporal artery ultrasonography examinations for diagnosis of giant cell arteritis: Analysis of 77 subjects. J Rheumatol. 2010; 37: 2326-2330.
98. Salvarani C, Silingardi M, Ghirarduzzi A, et al. Is duplex ultrasonography useful for the diagnosis of giant-cell arteritis? Ann Intern Med. 2002; 137: 232-238.
99. Schmidt WA, Kraft HE, Vorpahl K, Volker L, Gromnica-Ihle EJ,. Color duplex ultrasonography in the diagnosis of temporal arteritis. N Engl J Med. 1997; 337: 1336-1342.
100. Karassa FB, Matsagas MI, Schmidt WA, Ioannidis JP,. Meta-analysis: Test performance of ultrasonography for giant-cell arteritis. Ann Intern Med. 2005; 142: 359-369.
101. Pfadenhauer K, Weber H,. Duplex sonography of the temporal and occipital artery in the diagnosis of temporal arteritis. A prospective study. J Rheumatol. 2003; 30: 2177-2181.
102. Diamantopoulos AP, Haugeberg G, Hetland H, Soldal DM, Bie R, Myklebust G,. Diagnostic value of color Doppler ultrasonography of temporal arteries and large vessels in giant cell arteritis: A consecutive case series. Arthritis Care Res. 2014; 66: 113-119.
103. Muratore F, Boiardi L, Restuccia G, et al. Comparison between colour duplex sonography findings and different histological patterns of temporal artery. Rheumatology. 2013; 52: 2268-2274.
104. Restuccia G, Cavazza A, Boiardi L, et al. Small-vessel vasculitis surrounding an uninflamed temporal artery and isolated vasa vasorum vasculitis of the temporal artery: Two subsets of giant cell arteritis. Arthritis Rheum. 2012; 64: 549-556.
105. Hauenstein C, Reinhard M, Geiger J, et al. Effects of early corticosteroid treatment on magnetic resonance imaging and ultrasonography findings in giant cell arteritis. Rheumatology. 2012; 51: 1999-2003.
106. Bley TA, Wieben O, Uhl M, Thiel J, Schmidt D, Langer M,. High-resolution MRI in giant cell arteritis: Imaging of the wall of the superficial temporal artery. AJR Am J Roentgenol. 2005; 184: 283-287.
107. Geiger J, Ness T, Uhl M, et al. Involvement of the ophthalmic artery in giant cell arteritis visualized by 3T MRI. Rheumatology. 2009; 48: 537-541.
108. Narvaez J, Narvaez JA, Nolla JM, Sirvent E, Reina D, Valverde J,. Giant cell arteritis and polymyalgia rheumatica: Usefulness of vascular magnetic resonance imaging studies in the diagnosis of aortitis. Rheumatology. 2005; 44: 479-483.
109. Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of (1)(8)F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A systematic review and meta-analysis. Eur J Nucl Med Mol Imaging. 2011; 38: 1764-1772.
110. Blockmans D, De Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H,. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: A prospective study in 35 patients. Rheumatology. 2007; 46: 672-677.
111. Nishino H, DeRemee RA, Rubino FA, Parisi JE,. Wegener's granulomatosis associated with vasculitis of the temporal artery: Report of five cases. Mayo Clin Proc. 1993; 68: 115-121.
112. Genereau T, Martin A, Lortholary O, Noel V, Guillevin L,. Temporal arteritis symptoms in a patient with hepatitis C virus associated type II cryoglobulinemia and small vessel vasculitis. J Rheumatol. 1998; 25: 183-185.
113. Haugeberg G, Bie R, Johnsen V,. Vasculitic changes in the temporal artery in polyarteritis nodosa. Scand J Rheumatol. 1997; 26: 383-385.
114. Genereau T, Lortholary O, Pottier MA, et al. Temporal artery biopsy: A diagnostic tool for systemic necrotizing vasculitis. French Vasculitis Study Group. Arthritis Rheum. 1999; 42: 2674-2681.
115. Nagel MA, Bennett JL, Khmeleva N, et al. Multifocal VZV vasculopathy with temporal artery infection mimics giant cell arteritis. Neurology. 2013; 80: 2017-2021.
116. Salazar R, Russman AN, Nagel MA, et al. Varicella zoster virus ischemic optic neuropathy and subclinical temporal artery involvement. Arch Neurol. 2011; 68: 517-520.
117. Mathias M, Nagel MA, Khmeleva N, et al. VZV multifocal vasculopathy with ischemic optic neuropathy, acute retinal necrosis and temporal artery infection in the absence of zoster rash. J Neurol Sci. 2013; 325: 180-182.
118. Masood I, While B, Mudhar HS,. Perivascular mantle cell lymphoma affecting a temporal artery-A highly unusual cause of temporal headache. Cardiovasc Pathol. 2011; 20: 244-246.
119. Tannenbaum CB, Trudel MA, Kapusta MA,. Lymphomatous perivascular infiltration involving the temporal artery. J Rheumatol. 1996; 23: 2009-2010.
120. Neri A, Rubino P, Macaluso C, Gandolfi SA,. Light-chain amyloidosis mimicking giant cell arteritis in a bilateral anterior ischemic optic neuropathy case. BMC Ophthalmol. 2013; 13: 82.
121. Audemard A, Boutemy J, Galateau-Salle F, Macro M, Bienvenu B,. AL amyloidosis with temporal artery involvement simulates giant-cell arteritis. Joint Bone Spine. 2012; 79: 195-197.
122. Churchill CH, Abril A, Krishna M, Callman ML, Ginsburg WW,. Jaw claudication in primary amyloidosis: Unusual presentation of a rare disease. J Rheumatol. 2003; 30: 2283-2286.
123. Salvarani C, Gabriel SE, Gertz MA, Bjornsson J, Li CY, Hunder GG,. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum. 1994; 37: 1621-1626.
124. Roth AM, Milsow L, Keltner JL,. The ultimate diagnoses of patients undergoing temporal artery biopsies. Arch Ophthalmol. 1984; 102: 901-903.
125. Al-Absi AI, Wall BM, Cooke CR,. Medial arterial calcification mimicking temporal arteritis. Am J Kidney Dis. 2004; 44: e73-e78.
126. Awwad ST, Ghosn S, Hogan RN,. Calciphylaxis of the temporal artery masquerading as temporal arteritis. Clin Experiment Ophthalmol. 2010; 38: 511-513.
127. Kawai H, Hamasaki T, Imamura J, et al. Three cases of spontaneous superficial temporal artery aneurysm with literature review. Neurol Med Chir (Tokyo). 2013.
128. Delis A, Pollard CM, Prasad A, Sobonya RE, Leon LR Jr,. Isolated superficial temporal artery dissec tion masquerading as giant cell arteritis. Vascular. 2009; 17: 296-299.
129. Jalava-Karvinen P, Kemppainen J, Saario R, Kotilainen P,. Metastasis in the temporal bone mimicking temporal arteritis. J Clin Rheumatol. 2010; 16: 19-21.
130. Goupille P, Jeannou J, Brunais J, Valat JP,. Sphenoid abcess mimicking giant cell temporal arteritis. Clin Exp Rheumatol. 1996; 14: 579-580.
131. Mukhtyar C, Guillevin L, Cid MC, et al. EULAR recommendations for the management of large vessel vasculitis. Ann Rheum Dis. 2009; 68: 318-323.
132. Dasgupta B, Borg FA, Hassan N, et al. BSR and BHPR guidelines for the management of giant cell arteritis. Rheumatology. 2010; 49: 1594-1597.
133. Hunder GG, Sheps SG, Allen GL, Joyce JW,. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: Comparison in a prospective study. Ann Intern Med. 1975; 82: 613-618.
134. Foroozan R, Deramo VA, Buono LM, et al. Recovery of visual function in patients with biopsy-proven giant cell arteritis. Ophthalmology. 2003; 110: 539-542.
135. Chevalet P, Barrier JH, Pottier P, et al. A randomized, multicenter, controlled trial using intravenous pulses of methylprednisolone in the initial treatment of simple forms of giant cell arteritis: A one year followup study of 164 patients. J Rheumatol. 2000; 27: 1484-1491.
136. Mazlumzadeh M, Hunder GG, Easley KA, et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: A double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum. 2006; 54: 3310-3318.
137. Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res. 2010; 62: 1515-1526.
138. Proven A, Gabriel SE, Orces C, O'Fallon WM, Hunder GG,. Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes. Arthritis Rheum. 2003; 49: 703-708.
139. Roche NE, Fulbright JW, Wagner AD, Hunder GG, Goronzy JJ, Weyand CM,. Correlation of interleukin-6 production and disease activity in polymyalgia rheumatica and giant cell arteritis. Arthritis Rheum. 1993; 36: 1286-1294.
140. Hoffman GS, Cid MC, Hellmann DB, et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum. 2002; 46: 1309-1318.
141. Jover JA, Hernandez-Garcia C, Morado IC, Vargas E, Banares A, Fernandez-Gutierrez B,. Combined treatment of giant-cell arteritis with methotrexate and prednisone. A randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2001; 134: 106-114.
142. Spiera RF, Mitnick HJ, Kupersmith M, et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001; 19: 495-501.
143. Mahr AD, Jover JA, Spiera RF, et al. Adjunctive methotrexate for treatment of giant cell arteritis: An individual patient data meta-analysis. Arthritis Rheum. 2007; 56: 2789-2797.
144. Yates M, Loke YK, Watts RA, Macgregor AJ,. Prednisolone combined with adjunctive immunosuppression is not superior to prednisolone alone in terms of efficacy and safety in giant cell arteritis: Meta-analysis. Clin Rheumatol. 2013; 33: 227-236.
145. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: A randomized trial. Ann Intern Med. 2007; 146: 621-630.
146. de Boysson H, Boutemy J, Creveuil C, et al. Is there a place for cyclophosphamide in the treatment of giant-cell arteritis? A case series and systematic review. Semin Arthritis Rheum. 2013; 43: 105-112.
147. Unizony S, Arias-Urdaneta L, Miloslavsky E, et al. Tocilizumab for the treatment of large-vessel vasculitis (giant cell arteritis, Takayasu arteritis) and polymyalgia rheumatica. Arthritis Care Res. 2012; 64: 1720-1729.
148. Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell arteritis trial. Int J Rheumatol. 2013; 2013: 912562.
149. Matteson EL, Gold KN, Bloch DA, Hunder GG,. Long-term survival of patients with giant cell arteritis in the American College of Rheumatology giant cell arteritis classification criteria cohort. Am J Med. 1996; 100: 193-196.
150. Liozon E, Loustaud-Ratti V, Ly K, et al. Visual prognosis in extremely old patients with temporal (giant cell) arteritis. J Am Geriatr Soc. 2003; 51: 722-723.
151. Liozon E, Herrmann F, Ly K, et al. Risk factors for visual loss in giant cell (temporal) arteritis: A prospective study of 174 patients. Am J Med. 2001; 111: 211-217.
152. Cid MC, Font C, Oristrell J, et al. Association between strong inflammatory response and low risk of developing visual loss and other cranial ischemic complications in giant cell (temporal) arteritis. Arthritis Rheum. 1998; 41: 26-32.
153. Salvarani C, Cimino L, Macchioni P, et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum. 2005; 53: 293-297.
154. Lopez-Diaz MJ, Llorca J, Gonzalez-Juanatey C, Pena-Sagredo JL, Martin J, Gonzalez-Gay MA,. The erythrocyte sedimentation rate is associated with the development of visual complications in biopsy-proven giant cell arteritis. Semin Arthritis Rheum. 2008; 38: 116-123.
155. Breuer GS, Nesher R, Reinus K, Nesher G,. Association between histological features in temporal artery biopsies and clinical features of patients with giant cell arteritis. IMAJ. 2013; 15: 271-274.
156. Blockmans D, de Ceuninck L, Vanderschueren S, Knockaert D, Mortelmans L, Bobbaers H,. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: A prospective study of 35 patients. Arthritis Rheum. 2006; 55: 131-137.
157. Kaiser M, Weyand CM, Bjornsson J, Goronzy JJ,. Platelet-derived growth factor, intimal hyperplasia, and ischemic complications in giant cell arteritis. Arthritis Rheum. 1998; 41: 623-633.
158. Makkuni D, Bharadwaj A, Wolfe K, Payne S, Hutchings A, Dasgupta B,. Is intimal hyperplasia a marker of neuro-ophthalmic complications of giant cell arteritis? Rheumatology. 2008; 47: 488-490.
159. Armstrong AT, Tyler WB, Wood GC, Harrington TM,. Clinical importance of the presence of giant cells in temporal arteritis. J Clin Pathol. 2008; 61: 669-671.
160. Chatelain D, Duhaut P, Schmidt J, et al. Pathological features of temporal arteries in patients with giant cell arteritis presenting with permanent visual loss. Ann Rheum Dis. 2009; 68: 84-88.
161. Braun N, Fritz P, Rieth A, et al. Predictors for treatment success and expression of glucocorticoid receptor in giant cell arteritis and polymyalgia rheumatica. J Rheumatol. 2009; 36: 2269-2276.
162. Espigol-Frigole G, Corbera-Bellalta M, Planas-Rigol E, et al. Increased IL-17A expression in temporal artery lesions is a predictor of sustained response to glucocorticoid treatment in patients with giant-cell arteritis. Ann Rheum Dis. 2013; 72: 1481-1487.
163. Cid MC, Hoffman MP, Hernandez-Rodriguez J, et al. Association between increased CCL2 (MCP-1) expression in lesions and persistence of disease activity in giant-cell arteritis. Rheumatology. 2006; 45: 1356-1363.
164. Ly KH, Regent A, Tamby MC, Mouthon L,. Pathogenesis of giant cell arteritis: More than just an inflammatory condition? Autoimmun Rev. 2010; 9: 635-645.
165. Weyand CM, Liao YJ, Goronzy JJ,. The immunopathology of giant cell arteritis: Diagnostic and therapeutic implications. J Neuro Ophthalmol. 2012; 32: 259-265.
166. Carmona FD, Gonzalez-Gay MA, Martin J,. Genetic component of giant cell arteritis. Rheumatology. 2014; 53: 6-18.
167. Gabriel SE, Espy M, Erdman DD, Bjornsson J, Smith TF, Hunder GG,. The role of parvovirus B19 in the pathogenesis of giant cell arteritis: A preliminary evaluation. Arthritis Rheum. 1999; 42: 1255-1258.
168. Mohan SV, Liao YJ, Kim JW, Goronzy JJ, Weyand CM,. Giant cell arteritis: Immune and vascular aging as disease risk factors. Arthritis Res Ther. 2011; 13: 231.
169. Ma-Krupa W, Jeon MS, Spoerl S, Tedder TF, Goronzy JJ, Weyand CM,. Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. J Exp Med. 2004; 199: 173-183.
170. Robertson CE, Michet CJ Jr, Hunt CH, Garza I,. (18)F-FDG PET/CT may be useful when evaluating a patient for giant cell arteritis. Headache. 2012; 52: 491-493.